Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06924541 · ClinicalTrials.gov registry record · NA

Choline Dose Ranging in Postmenopausal Women

A NA study of Menopause, sponsored by Julie Dumas.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06924541 is a NA study of Menopause that is actively recruiting participants, run by Julie Dumas. The registered enrollment target is 20 participants, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06924541, a NA study of Menopause, is actively recruiting participants, sponsored by Julie Dumas.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study will use a randomized placebo-controlled trial to examine smaller doses of choline and whether a signal in the brain is detectable using fMRI. This study will examine if an even smaller doses of choline can show these similar brain activation and connectivity patterns to the 1650 mg dose. This will be a dose ranging study of 550 mg and 1100 mg oral choline compared to placebo.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Choline

Study Locations (1)

Vermont

  • University of Vermont - Burlington

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-09-01
Est. Completion 2026-03-01
Phase NA

Sponsor

Julie Dumas

1 total trials

What the Registry Record Tells You About NCT06924541

The ClinicalTrials.gov registry entry for NCT06924541 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The listed sponsor is Julie Dumas, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06924541 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT06924541 about?

NCT06924541 is a clinical study titled "Choline Dose Ranging in Postmenopausal Women". This study will use a randomized placebo-controlled trial to examine smaller doses of choline and whether a signal in the brain is detectable using fMRI. This study will examine if an even smaller doses of choline can show these similar brain activation and connectivity patterns to the 1650 mg dose....

What is the current status of trial NCT06924541?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-01. Estimated completion is 2026-03-01.

What conditions does trial NCT06924541 study?

This clinical trial studies the following conditions: Menopause.

What interventions are being tested in trial NCT06924541?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Choline (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06924541?

This trial is sponsored by Julie Dumas, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06924541 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.